Gilead said at the time that "positive data emerging from the National Institute of Allergy and Infectious Diseases'" study of remdesivir indicates the treatment has "met its primary endpoint" and also noted that its own study showed that nearly two thirds of the nearly 400 severe-stage coronavirus patients using remdisivir were discharged from hospital after using the treatment early, a better rate than those given the drug at a later stage.

The studies contradicted reports leaked on the World Health Organization website last month that suggested remdesivir had little success in a China-based study that was halted after authorities said there weren't enough patients enrolled